Myogenica Overview

  • Year Founded
  • 2022

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Early Stage VC

  • Investors
  • 4

Myogenica General Information

Description

Developer of a muscle regeneration technology intended for treating muscular dystrophy. The company's technology utilizes induced pluripotent stem cells expressing PAX7 to regenerate muscle tissue, enabling patients with muscular dystrophy to improve muscle function and quality of life through a single treatment.

Contact Information

Website
www.myogenica.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 8 the Green
  • Suite A
  • Dover, DE 19901
  • United States
+1 (216)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
HealthTech, Life Sciences
Corporate Office
  • 8 the Green
  • Suite A
  • Dover, DE 19901
  • United States
+1 (216)

Myogenica Timeline

2023202420252026
Financing Round

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Myogenica Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC 01-Jan-2024 Completed Clinical Trials - Phase 1
3. Seed Round 28-Mar-2022 Completed Pre-Clinical Trials
2. Accelerator/Incubator Completed Pre-Clinical Trials
1. University Spin-Out 01-Jan-2022 Completed Pre-Clinical Trials
To view Myogenica’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Myogenica Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
Second Fiduciary Exchange Fund Hedge Fund Minority
SeedFolio Venture Capital Minority
University of Minnesota University
University Enterprise Laboratories Accelerator/Incubator
To view Myogenica’s complete investors history, request access »

Ready to get started?

Request a free trial

Myogenica FAQs

  • When was Myogenica founded?

    Myogenica was founded in 2022.

  • Where is Myogenica headquartered?

    Myogenica is headquartered in Dover, DE.

  • What industry is Myogenica in?

    Myogenica’s primary industry is Drug Discovery.

  • Is Myogenica a private or public company?

    Myogenica is a Private company.

  • What is Myogenica’s current revenue?

    The current revenue for Myogenica is .

  • How much funding has Myogenica raised over time?

    Myogenica has raised $100K.

  • Who are Myogenica’s investors?

    Second Fiduciary Exchange Fund, SeedFolio, University of Minnesota, and University Enterprise Laboratories have invested in Myogenica.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process